Almirall S.A. stock (ES0157097017): Q1 2026 sales up 2.2% YoY to €291M

Almirall S.A. posted Q1 2026 net sales of €291 million, up 2.2% year-over-year, driven by European dermatology and biologics growth, with guidance reaffirmed per company results.

Almirall S.A. released its Q1 2026 financial results, reporting net sales of €291.0 million, a 2.2% increase year-over-year. The growth was fueled by a 19.3% rise in the European dermatology business and strong biologics performance, including products like Ebglyss and Ilumetri, according to BioSpace as of May 2026 and TradingView as of May 2026. The company reaffirmed its full-year guidance, signaling confidence in its trajectory.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall S.A.
• Sector/industry: Healthcare / Dermatology
• Headquarters/country: Spain
• Core markets: Europe, US, emerging markets
• Key revenue drivers: Prescription dermatology drugs
• Home exchange/listing venue: Bolsa de Madrid (ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall S.A. operates as a pharmaceutical company dedicated to medical dermatology, developing and commercializing treatments for skin diseases such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1944 and headquartered in Barcelona, Spain, the firm focuses on moderate-to-severe conditions with a portfolio blending marketed products and an advancing R&D pipeline.

Revenue stems primarily from Europe, with expansions into the US and emerging markets. The model emphasizes innovative biologics and small molecules, supported by strategic partnerships and regulatory approvals, as noted in company overviews from ad-hoc-news.de as of recent updates.

Main revenue and product drivers for Almirall S.A.

Key products include Skilarence (dimethyl fumarate) for psoriasis, Solaraze (diclofenac) for actinic keratosis, and biologics like Ebglyss (lebrikizumab) for atopic dermatitis, which gained European approvals and drove Q1 growth. In full-year 2024 results published February 28, 2025, sales reached €1.02 billion, up 8% YoY, with core dermatology at 85% of revenue per company IR.

Q1 2026 results highlighted 19.3% YoY growth in European dermatology and biologics strength, aligning with reaffirmed guidance, according to TradingView as of May 2026.

Why Almirall S.A. matters for US investors

Almirall S.A. offers US investors exposure to Europe's dermatology innovation via its Madrid listing (ALM), accessible through major brokers without a direct ADR. The sector's global demand, including US market potential for its pipeline, ties into rising skincare needs amid an aging population.

Industry trends and competitive position

The dermatology market grows with demand for biologics targeting inflammatory conditions, where Almirall competes via specialized focus against larger pharma peers. Its pipeline advancements position it well in psoriasis and atopic dermatitis segments with high unmet needs.

Conclusion

Almirall S.A. demonstrated steady Q1 2026 performance with 2.2% sales growth to €291 million, propelled by dermatology and biologics amid reaffirmed guidance. The company's niche in medical dermatology, backed by a solid pipeline and European stronghold, supports its positioning. US investors gain access to this growth via accessible trading venues.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.